-
IGF signals in GIST
Insulin-related growth factor family: potential role in GIST Several 2008 papers suggest that the insulin-related growth factors and associated receptors may be treatment targets for GISTs, including wild-type adult GISTs as well as pediatric GISTs and Carney Triad. This is exciting because development of drugs relevant to the insulin-related growth factor (IGF) family is already […]
Continue reading -
Sorafenib Is Promising
Sorafenib for GIST At the January 2008 ASCO GI Cancers Symposium, Dr. Nimeiri presented a paper describing the first preliminary results of the ongoing Phase II trial of sorafenib (brand name Nexavar) for gastrointestinal stromal tumor. Click the title below for the full abstract. After linking to the abstract on the ASCO site, you can […]
Continue reading -
Team GIST Completes Sarcoma Tour 2006
Day 1: Arrival at Legoland (July 1st, 2006) Our first full day in Denmark was largely occupied by travel and logistics. We took a train from Copenhagen to Vejle where we first met our outstanding bus driver Jens. Also on the bus were Guy and Nigel, a father and son team from New Zealand. It […]
Continue reading -
Vermont Hills “Invaded” by Team Sarcoma
It was not your usual sight…about 50 bicycle riders traversing the hilly terrain of Vermont back in July. Though some might have been tempted, with tongue in cheek, to opine that they must have been some Tour de France riders who made a wrong turn on the outskirts of Paris, they were actually more like […]
Continue reading -
FDA Approves Adjuvant Imatinib
On December 19, 2008 the US FDA announced approval of the use of imatinib (Gleevec) as adjuvant treatment (prescribed after complete surgical resection) to prevent recurrence of GIST. Below is a link to the brief announcement. More details should emerge soon. http://www.fda.gov:80/bbs/topics/NEWS/2008/NEW01931.html
Continue reading -
Attending CTOS conference: a whirlwind experience!
Attending CTOS conference: a whirlwind experience! by Barbara Dore I had the chance to represent GSI at CTOS (Connective Tissue Oncology Society), which was held in London November 13 -15th in the Landmark Hotel. The Landmark Hotel is rather a grand red-brick Victorian Railway hotel, built at the terminus of the Grand Central Railway line […]
Continue reading -
CTOS and SARC Meet in London
Barbara Dore’ (a member of GSI’s board and our science committee) attended the CTOS meeting in London November 13-15 on behalf of GIST Support International. This news story highlights some of the new science findings Barbara gleaned at CTOS, which is the world’s premier gathering of sarcoma experts. You can view the program listing at […]
Continue reading -
Duensing’s New GIST Findings
Anette Duensing, MD is a research pathologist who is a highly valued member of the Science Committee of GIST Support International. A native of Germany, Dr. Duensing did a post-doc at the Dana-Farber lab of Jonathan Fletcher, MD before joining the faculty at the University of Pittsburgh. New Findings on GIST Quiescence Dr. Anette Duensing […]
Continue reading -
Adjuvant Gleevec Trial News
The Z9001 trial of adjuvant Gleevec (imatinib) administered for one year after surgery has been unblinded early after an interim analysis showed a striking difference in recurrence rates for subjects who received Gleevec (97% recurrence-free) versus those who received placebo (83% recurrence-free). Patients currently taking placebo will receive one year of Gleevec. Novartis, manufacturer of […]
Continue reading -
Z9000 Adjuvant Imatinib Trial
Z9000 Trial of Adjuvant Imatinib: Interim Results At the ASCO GI Cancers Symposium in January 2008 Ronald DeMatteo, M.D. presented early results for the Z9000 trial of adjuvant Gleevec for high-risk tumors. Click the presentation title below to link to the abstract. After linking to the abstract on the ASCO site, you can click the […]
Continue reading